|
1
|
DeSantis CE, Ma J, Goding Sauer A, Newman
LA and Jemal A: Breast cancer statistics, 2017, racial disparity in
mortality by state. CA Cancer J Clin. 67:439–448. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chavez KJ, Garimella SV and Lipkowitz S:
Triple negative breast cancer cell lines: One tool in the search
for better treatment of triple negative breast cancer. Breast Dis.
32:35–48. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rajappa S, Bajpai J, Basade M, Ganvir M,
Goswami C, Murali A, Rathi AK, Kaushal V, Jain S, Parikh PM, et al:
Practical consensus recommendations regarding the use of hormonal
therapy in metastatic breast cancer. South Asian J Cancer.
7:137–141. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alfarsi L, Johnston S, Liu DX, Rakha E and
Green AR: Current issues with luminal subtype classification in
terms of prediction of benefit from endocrine therapy in early
breast cancer. Histopathology. 73:545–558. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bowers JL, Tyulmenkov VV, Jernigan SC and
Klinge CM: Resveratrol acts as a mixed agonist/antagonist for
estrogen receptors α and β. Endocrinology. 141:3657–3667. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu R and Serrero G: Resveratrol, a natural
product derived from grape, exhibits antiestrogenic activity and
inhibits the growth of human breast cancer cells. J Cell Physiol.
179:297–304. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sirerol JA, Rodríguez ML, Mena S, Asensi
MA, Estrela JM and Ortega AL: Role of natural stilbenes in the
prevention of cancer. Oxid Med Cell Longev. 2016:31289512016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ko JH, Sethi G, Um JY, Shanmugam MK,
Arfuso F, Kumar AP, Bishayee A and Ahn KS: The role of resveratrol
in cancer therapy. Int J Mol Sci. 18:25892017. View Article : Google Scholar :
|
|
9
|
Hsieh TC, Wong C, John Bennett D and Wu
JM: Regulation of p53 and cell proliferation by resveratrol and its
derivatives in breast cancer cells: An in silico and biochemical
approach targeting integrin αvβ3. Int J Cancer. 129:2732–2743.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yenugonda VM, Kong Y, Deb TB, Yang Y,
Riggins RB and Brown ML: Trans-resveratrol boronic acid
exhibits enhanced anti-proliferative activity on estrogen-dependent
MCF-7 breast cancer cells. Cancer Biol Ther. 13:925–934. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee PS, Chiou YS, Ho CT and Pan MH:
Chemoprevention by resveratrol and pterostilbene: Targeting on
epigenetic regulation. Biofactors. 44:26–35. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chin YT, Hsieh MT, Yang SH, Tsai PW, Wang
SH, Wang CC, Lee YS, Cheng GY, HuangFu WC, London D, et al:
Anti-proliferative and gene expression actions of resveratrol in
breast cancer cells in vitro. Oncotarget. 5:12891–12907. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu Y, Liu Y, Chen H, Yao X, Xiao Y, Zeng
X, Zheng Q, Wei Y, Song C, Zhang Y, et al: Synthetic resveratrol
derivatives and their biological activities: A review. Open J Med
Chem. 05:97–105. 2015. View Article : Google Scholar
|
|
14
|
Walle T: Bioavailability of resveratrol.
Ann NY Acad Sci. 1215:9–15. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Licznerska B, Szaefer H, Wierzchowski M,
Mikstacka R, Papierska K and Baer-Dubowska W: Evaluation of the
effect of the new methoxy-stilbenes on expression of receptors and
enzymes involved in estrogen synthesis in cancer breast cells. Mol
Cell Biochem. 444:53–62. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jo SJ, Park PG, Cha HR, Ahn SG, Kim MJ,
Kim H, Koo JS, Jeong J, Park JH, Dong SM, et al: Cellular inhibitor
of apoptosis protein 2 promotes the epithelial-mesenchymal
transition in triple-negative breast cancer cells through
activation of the AKT signaling pathway. Oncotarget. 8:78781–78795.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Paul S, Mizuno CS, Lee HJ, Zheng X,
Chajkowisk S, Rimoldi JM, Conney A, Suh N and Rimando AM: In vitro
and in vivo studies on stilbene analogs as potential treatment
agents for colon cancer. Eur J Med Chem. 45:3702–3708. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mizuno CS, Ma G, Khan S, Patny A, Avery MA
and Rimando AM: Design, synthesis, biological evaluation and
docking studies of pterostilbene analogs inside PPARalpha. Bioorg
Med Chem. 16:3800–3808. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Roberti M, Pizzirani D, Simoni D, Rondanin
R, Baruchello R, Bonora C, Buscemi F, Grimaudo S and Tolomeo M:
Synthesis and biological evaluation of resveratrol and analogues as
apoptosis-inducing agents. J Med Chem. 46:3546–3554. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pettit GR, Grealish MP, Jung MK, Hamel E,
Pettit RK, Chapuis JC and Schmidt JM: Antineoplastic agents. 465.
Structural modification of resveratrol: Sodium resverastatin
phosphate. J Med Chem. 45:2534–2542. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tate CR, Rhodes LV, Segar HC, Driver JL,
Pounder FN, Burow ME and Collins-Burow BM: Targeting
triple-negative breast cancer cells with the histone deacetylase
inhibitor panobinostat. Breast Cancer Res. 14:R792012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sauter ER: Breast cancer prevention:
Current approaches and future directions. Eur J Breast Health.
14:64–71. 2018.PubMed/NCBI
|
|
25
|
Saluzzo J, Hallman KM, Aleck K, Dwyer B,
Quigley M, Mladenovik V, Siebert AE and Dinda S: The regulation of
tumor suppressor protein, p53, and estrogen receptor (ERα) by
resveratrol in breast cancer cells. Genes Cancer. 7:414–425.
2016.PubMed/NCBI
|
|
26
|
Leon-Galicia I, Diaz-Chavez J,
Albino-Sanchez ME, Garcia-Villa E, Bermudez-Cruz R, Garcia-Mena J,
Herrera LA, García-Carrancá A and Gariglio P: Resveratrol decreases
Rad51 expression and sensitizes cisplatin-resistant MCF-7 breast
cancer cells. Oncol Rep. 39:3025–3033. 2018.PubMed/NCBI
|
|
27
|
Bhattacharyya A, Ear US, Koller BH,
Weichselbaum RR and Bishop DK: The breast cancer susceptibility
gene BRCA1 is required for subnuclear assembly of Rad51 and
survival following treatment with the DNA cross-linking agent
cisplatin. J Biol Chem. 275:23899–23903. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
De Amicis F, Giordano F, Vivacqua A,
Pellegrino M, Panno ML, Tramontano D, Fuqua SA and Andò S:
Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation,
inhibits estrogen receptor alpha gene expression via
p38MAPK/CK2 signaling in human breast cancer cells.
FASEB J. 25:3695–3707. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ronghe A, Chatterjee A, Bhat NK, Padhye S
and Bhat HK: Tamoxifen synergizes with
4-(E)-{(4-hydroxyphenylimino)-methylbenzene, 1,2-diol} and
4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, novel azaresveratrol
analogs, in inhibiting the proliferation of breast cancer cells.
Oncotarget. 7:51747–51762. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ronghe A, Chatterjee A, Singh B, Dandawate
P, Murphy L, Bhat NK, Padhye S and Bhat HK: Differential regulation
of estrogen receptors α and β by
4-(E)-{(4-hydroxyphenylimino)-methylbenzene,1,2-diol}, a novel
resveratrol analog. J Steroid Biochem Mol Biol. 144:500–512. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chin YT, Yang SH, Chang TC, Changou CA,
Lai HY, Fu E, HuangFu WC, Davis PJ, Lin HY and Liu LF: Mechanisms
of dihydrotestosterone action on resveratrol-induced
antiproliferation in breast cancer cells with different ERα status.
Oncotarget. 6:35866–35879. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Simoni D, Roberti M, Invidiata FP,
Rondanin R, Baruchello R, Malagutti C, Mazzali A, Rossi M, Grimaudo
S, Capone F, et al: Heterocycle-containing retinoids. Discovery of
a novel isoxazole arotinoid possessing potent apoptotic activity in
multidrug and drug-induced apoptosis-resistant cells. J Med Chem.
44:2308–2318. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kumar A, Rimando AM and Levenson AS:
Resveratrol and pterostilbene as a microRNA-mediated
chemopreventive and therapeutic strategy in prostate cancer. Ann NY
Acad Sci. 1403:15–26. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moon D, McCormack D, McDonald D and
McFadden D: Pterostilbene induces mitochondrially derived apoptosis
in breast cancer cells in vitro. J Surg Res. 180:208–215. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hong YB, Kang HJ, Kim HJ, Rosen EM,
Dakshanamurthy S, Rondanin R, Baruchello R, Grisolia G, Daniele S
and Bae I: Inhibition of cell proliferation by a resveratrol analog
in human pancreatic and breast cancer cells. Exp Mol Med.
41:151–160. 2009. View Article : Google Scholar : PubMed/NCBI
|
